Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tiikkainen, M.
Right arrow Articles by Yki-Järvinen, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tiikkainen, M.
Right arrow Articles by Yki-Järvinen, H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:2169-2176, 2004
© 2004 by the American Diabetes Association, Inc.

Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes

Mirja Tiikkainen1, Anna-Maija Häkkinen2, Elena Korsheninnikova1,3, Tuulikki Nyman3, Sari Mäkimattila1, and Hannele Yki-Järvinen1

1 Department of Medicine, Division of Diabetes, University of Helsinki, Helsinki, Finland
2 Department of Medicine, Division of Oncology, University of Helsinki, Helsinki, Finland
3 Minerva Research Institute, Helsinki, Finland

Both rosiglitazone and metformin increase hepatic insulin sensitivity, but their mechanism of action has not been compared in humans. The objective of this study was to compare the effects of rosiglitazone and metformin treatment on liver fat content, hepatic insulin sensitivity, insulin clearance, and gene expression in adipose tissue and serum adiponectin concentrations in type 2 diabetes. A total of 20 drug-naive patients with type 2 diabetes (age 48 ± 3 years, fasting plasma glucose 152 ± 9 mg/dl, BMI 30.6 ± 0.8 kg/m2) were treated in a double-blind randomized fashion with either 8 mg rosiglitazone or 2 g metformin for 16 weeks. Both drugs similarly decreased HbA1c, insulin, and free fatty acid concentrations. Body weight decreased in the metformin (84 ± 4 vs. 82 ± 4 kg, P < 0.05) but not the rosiglitazone group. Liver fat (proton spectroscopy) was decreased with rosiglitazone by 51% (15 ± 3 vs. 7 ± 1%, 0 vs. 16 weeks, P = 0.003) but not by metformin (13 ± 3 to 14 ± 3%, NS). Rosiglitazone (16 ± 2 vs. 20 ± 1 ml · kg–1 · min–1, P = 0.02) but not metformin increased insulin clearance by 20%. Hepatic insulin sensitivity in the basal state increased similarly in both groups. Insulin-stimulated glucose uptake increased significantly with rosiglitazone but not with metformin. Serum adiponectin concentrations increased by 123% with rosiglitazone but remained unchanged during metformin treatment. The decrease of serum adiponectin concentrations correlated with the decrease in liver fat (r = –0.74, P < 0.001). Rosiglitazone but not metformin significantly increased expression of peroxisome proliferator–activated receptor-{gamma}, adiponectin, and lipoprotein lipase in adipose tissue. In conclusion, rosiglitazone but not metformin decreases liver fat and increases insulin clearance. The decrease in liver fat by rosiglitazone is associated with an increase in serum adiponectin concentrations. Both agents increase hepatic insulin sensitivity, but only rosiglitazone increases peripheral glucose uptake.

Address correspondence and reprint requests to Hannele Yki-Järvinen, MD, FRCP, Department of Medicine, University of Helsinki, P.O. Box 340, FIN-00029 HUCH, Helsinki, Finland. E-mail: ykijarvi{at}helsinki.fi


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
U. Riserus, D. Sprecher, T. Johnson, E. Olson, S. Hirschberg, A. Liu, Z. Fang, P. Hegde, D. Richards, L. Sarov-Blat, et al.
Activation of Peroxisome Proliferator-Activated Receptor (PPAR){delta} Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men
Diabetes, February 1, 2008; 57(2): 332 - 339.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza
Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes
Diabetes, January 1, 2008; 57(1): 24 - 31.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Kotronen, J. Westerbacka, R. Bergholm, K. H. Pietilainen, and H. Yki-Jarvinen
Liver Fat in the Metabolic Syndrome
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3490 - 3497.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. J. Lessard, D. A. Rivas, Z.-P. Chen, A. Bonen, M. A. Febbraio, D. W. Reeder, B. E. Kemp, B. B. Yaspelkis III, and J. A. Hawley
Tissue-Specific Effects of Rosiglitazone and Exercise in the Treatment of Lipid-Induced Insulin Resistance
Diabetes, July 1, 2007; 56(7): 1856 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Nonalcoholic Fatty Liver Disease and Insulin Resistance in Youth
Diabetes Care, June 1, 2007; 30(6): 1663 - 1669.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L.-F. Liu, A. Purushotham, A. A. Wendel, and M. A. Belury
Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice
Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1671 - G1682.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, C. Day, and G. Arcaro
Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients
Diabetes Care, May 1, 2007; 30(5): 1212 - 1218.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, and Y. Deshaies
Involvement of adipose tissues in the early hypolipidemic action of PPAR{gamma} agonism in the rat
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1408 - R1417.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. G. Tolman, V. Fonseca, A. Dalpiaz, and M. H. Tan
Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease
Diabetes Care, March 1, 2007; 30(3): 734 - 743.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
L. Juurinen, M. Tiikkainen, A.-M. Hakkinen, A. Hakkarainen, and H. Yki-Jarvinen
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E829 - E835.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Freemark
Pharmacotherapy of Childhood Obesity: An evidence-based, conceptual approach
Diabetes Care, February 1, 2007; 30(2): 395 - 402.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Sharma and B. Staels
Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Kolak, H. Yki-Jarvinen, K. Kannisto, M. Tiikkainen, A. Hamsten, P. Eriksson, and R. M. Fisher
Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissue in Vivo in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 720 - 724.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. M. Utzschneider and S. E. Kahn
The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. Belfort, S. A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas, A. Gastaldelli, F. Tio, J. Pulcini, et al.
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
N. Engl. J. Med., November 30, 2006; 355(22): 2297 - 2307.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. J. McCullough
Thiazolidinediones for Nonalcoholic Steatohepatitis -- Promising but Not Ready for Prime Time
N. Engl. J. Med., November 30, 2006; 355(22): 2361 - 2363.
[Full Text] [PDF]

Home page
 J. Lipid Res.Home page
G. Ranganathan, R. Unal, I. Pokrovskaya, A. Yao-Borengasser, B. Phanavanh, B. Lecka-Czernik, N. Rasouli, and P. A. Kern
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment
J. Lipid Res., November 1, 2006; 47(11): 2444 - 2450.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Gastaldelli, Y. Miyazaki, A. Mahankali, R. Berria, M. Pettiti, E. Buzzigoli, E. Ferrannini, and R. A. DeFronzo
The Effect of Pioglitazone on the Liver: Role of adiponectin
Diabetes Care, October 1, 2006; 29(10): 2275 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
K G Hollingsworth, M Z Abubacker, I Joubert, M E D Allison, and D J Lomas
Low-carbohydrate diet induced reduction of hepatic lipid content observed with a rapid non-invasive MRI technique.
Br. J. Radiol., September 1, 2006; 79(945): 712 - 715.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
D. J. Jenkins, A. R Josse, R. Labelle, A. Marchie, L. S. Augustin, and C. W. Kendall
Nonalcoholic fatty liver, nonalcoholic steatohepatitis, ectopic fat, and the glycemic index
Am. J. Clinical Nutrition, July 1, 2006; 84(1): 3 - 4.
[Full Text] [PDF]

Home page
 J. Physiol.Home page
M. Daval, F. Foufelle, and P. Ferre
Functions of AMP-activated protein kinase in adipose tissue
J. Physiol., July 1, 2006; 574(1): 55 - 62.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. D. van Poelje, S. C. Potter, V. C. Chandramouli, B. R. Landau, Q. Dang, and M. D. Erion
Inhibition of Fructose 1,6-Bisphosphatase Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats
Diabetes, June 1, 2006; 55(6): 1747 - 1754.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Gastaldelli, Y. Miyazaki, M. Pettiti, E. Santini, D. Ciociaro, R. A. DeFronzo, and E. Ferrannini
The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 806 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. F. Samaha, P. O. Szapary, N. Iqbal, M. M. Williams, L. T. Bloedon, A. Kochar, M. L. Wolfe, and D. J. Rader
Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 624 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
A. S Greenberg and M. S Obin
Obesity and the role of adipose tissue in inflammation and metabolism
Am. J. Clinical Nutrition, February 1, 2006; 83(2): 461S - 465S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E42 - E46.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. P. M. Viljanen, K. A. Virtanen, M. J. Jarvisalo, K. Hallsten, R. Parkkola, T. Ronnemaa, F. Lonnqvist, P. Iozzo, E. Ferrannini, and P. Nuutila
Rosiglitazone Treatment Increases Subcutaneous Adipose Tissue Glucose Uptake in Parallel with Perfusion in Patients with Type 2 Diabetes: A Double-Blind, Randomized Study with Metformin
J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6523 - 6528.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. S. Reingold, J. M. McGavock, S. Kaka, T. Tillery, R. G. Victor, and L. S. Szczepaniak
Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method
Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E935 - E939.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Lautamaki, K.E. J. Airaksinen, M. Seppanen, J. Toikka, M. Luotolahti, E. Ball, R. Borra, R. Harkonen, P. Iozzo, M. Stewart, et al.
Rosiglitazone Improves Myocardial Glucose Uptake in Patients With Type 2 Diabetes and Coronary Artery Disease: A 16-Week Randomized, Double-Blind, Placebo-Controlled Study
Diabetes, September 1, 2005; 54(9): 2787 - 2794.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease
Diabetes Care, June 1, 2005; 28(6): 1518 - 1523.
[Full Text] [PDF]

Home page
 DiabetesHome page
H.-J. Pan, P. Reifsnyder, D. E. Vance, Q. Xiao, and E. H. Leiter
Pharmacogenetic Analysis of Rosiglitazone-Induced Hepatosteatosis in New Mouse Models of Type 2 Diabetes
Diabetes, June 1, 2005; 54(6): 1854 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Westerbacka, K. Lammi, A.-M. Hakkinen, A. Rissanen, I. Salminen, A. Aro, and H. Yki-Jarvinen
Dietary Fat Content Modifies Liver Fat in Overweight Nondiabetic Subjects
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2804 - 2809.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Yki-Jarvinen
Thiazolidinediones
N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.